Bevacizumab biosimilar - Mabscale
Latest Information Update: 18 Jul 2023
At a glance
- Originator Mabscale
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Non-small cell lung cancer
Most Recent Events
- 31 May 2023 Phase-III clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) in Russia (IV) (NCT05654454)
- 21 Dec 2022 Investigation in Non-small cell lung cancer in Russia (IV) (NCT05654454)
- 16 Dec 2022 Mabscale plans a phase III trial for Non-Small Cell Lung Cancer (Combination therapy, Newly diagnosed, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) in Russia (IV)(NCT05654454)